BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Celltech Agrees To Buyout By UCB For $2.7B In Cash
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Celltech Agrees To Buyout By UCB For $2.7B In Cash
May 19, 2004
By
Nuala Moran
No Comments
LONDON - Celltech Group plc, the UK's largest biotechnology company, has agreed to be taken over by UCB SA, of Brussels, Belgium, in an all-cash deal that values Celltech at about £1.5 billion (US$2.7 billion). (BioWorld Today)
BioWorld